NCT06016634View on ClinicalTrials.gov

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Sickle Cell DiseaseSickle Cell AnemiaOsteonecrosisIschemic NecrosisAvascular Necrosis
Interventions
DRUG

Alendronate Sodium

Administer oral alendronate 70 mg once a week x 24 weeks to all study participants

Trial Locations (1)

95817

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Doris Duke Charitable Foundation

OTHER

lead

University of California, Davis

OTHER

NCT06016634 - Alendronate for Osteonecrosis in Adults With Sickle Cell Disease | Biotech Hunter | Biotech Hunter